Navigation Links
'Seena' clinical trials named for pancreatic cancer advocate
Date:12/1/2011

all drugs combined. Patients will be given this treatment for a maximum of 6 months.
  • In the third treatment, the patient's tumor will be biopsied and analyzed using molecular profiling to determine the next most appropriate treatment. Patients also will receive a drug called Metformin during this part of the study.

    The plan is to attack all components of the cancer: the tumor cell, their support structure and their energy source.

    The clinical trial sites includes the Virginia G. Piper Cancer Center Clinical Trials, a partnership of TGen and Scottsdale Healthcare, where the principal investigator is TGen Physician-In-Chief Dr. Daniel Von Hoff, one of the world's leading authorities on pancreatic cancer. Dr. Von Hoff also is chief scientific officer at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

    Dr. Von Hoff said that TGen, through the Virginia G. Piper Cancer Center at Scottsdale Healthcare and its other PCRT partners, are making progress in the quest to end this cancer: "We are to deliver a knockout punch by combining the best treatments we have against the disease. The contributions of Roger Magowitz represent significant acceleration toward our goal of finding better treatments, and ultimately a cure."

    The other clinical trial sites are:

    Virginia Piper Cancer Institute, Minneapolis, Minn., where the principal investigator is Dr. John Seng: "We are one of the nation's leading pancreatic cancer treatment centers. The new Seena clinical trial will allow patients to take a more active role in their health care, gain access to new drugs, treatments and disease management practices, and contribute to medical research."

    Evergreen Hematology & Oncology, Spokane, Wash., where the principal investigator is Dr. Stephen Anthony: "As the former Chief Medical Officer of TGen Drug Development, I know how meticulously this study will be organized and conducted, using every efficiency possi
    '/>"/>


  • Contact: Steve Yozwiak
    syozwiak@tgen.org
    602-343-8704
    The Translational Genomics Research Institute
    Source:Eurekalert

    Page: 1 2 3

    Related biology news :

    1. Vaccine targeting latent TB enters clinical testing
    2. Clinical trial for muscular dystrophy demonstrates safety of customized gene therapy
    3. BI-Clinical Offers 100% Coverage of All ACO Quality Measures Released by CMS
    4. Heart rate recovery predicts clinical worsening in pulmonary hypertension
    5. Worlds first stem cell bandage in human clinical trials
    6. Combination therapy shows potent tumor growth inhibition in preclinical studies
    7. CBIs Interactive Response Technologies for Clinical Trials - the Only IVR/IWR Event of Its Kind - Will Be in Philadelphia on November 14-15, 2011
    8. Study shows that new DNA test to identify Down syndrome in pregnancy is ready for clinical use
    9. Professor Peter J. Coffeys stem cell therapy for Age-Related Macular Degeneration expected to begin clinical trials in 2012
    10. AMIA advises FDA on clinical decision support
    11. Reports highlight the evolving role of clinical microbiology laboratories
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
    (Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
    (Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
    Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
    ... renowned climate researcher Caroline Leck of Stockholm University has ... results are truly sensational," says Dr Leck. "If confirmed ... efforts to achieve the political targets for climate." ... Earth,s mean surface temperature climbed sharply through the 1990s, ...
    ... one of the leaders in the field of neurosciences, ... of one of literature,s greatest authors, Virginia Woolf. The ... the literature she wrote and comments, letters and other ... medical status. The author uses current insights into depression, ...
    ... 25, 2013 /PRNewswire-iReach/ --   Find Heather on ... . She is a a third year physics major at the ... also learned after writing numerous twenty plus page lab reports, a life ... a career relating to patents and IP law. Last summer, she interned ...
    Cached Biology News:Global warming less extreme than feared? 2Global warming less extreme than feared? 3Global warming less extreme than feared? 4The Website You Have to Log Into 2The Website You Have to Log Into 3
    (Date:12/24/2014)... December 23, 2014 According to Ross Selinger, ... Affiliate of ITRA Global, the national office market continues to ... This is evidenced by the third quarter’s surprising 3.9% ... Low energy costs have held inflation down and the ... is the housing market remaining soft. , This solid economic ...
    (Date:12/24/2014)... (PRWEB) December 23, 2014 Pipette.com announces ... their Twitter followers can submit their #HolidayInTheLab pictures for ... their lab mates. , For those struggling to think ... the Pipette.com Holiday in the Lab Contest provides the ... Twitter followers to send pictures of their chemistree, ...
    (Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
    (Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
    Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
    ... 1 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO ... a conference call and webcast on Friday, October 2, ... update investors on the Company,s Phase 3 program for ... dial 1-416-644-3426 or 1-800-732-1073. A live audio webcast will ...
    ... Enerkem,s future biofuels plant will supply green energy to ... - Enerkem, a leading waste-to-biofuels and green chemicals technology company, ... that will heat a Strathcona County neighbourhood, using the residual ... Edmonton waste-to-biofuels plant. , The project received grant funding in ...
    ... YORK, Oct. 1 /PRNewswire-FirstCall/ - Healthnostics, Inc. (OTC PK: ... its strategy for the biomedical content layer of the ... major shift in strategy by MedBioWorld.com will consist of ... professional base to a wider, more general audience. This ...
    Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Phase 3 Update Conference Call 2Enerkem Announces Unique Community Energy Project 2Healthnostics Unveils Biomedical Content Strategy for Medbioworld.com 2
    Recombinant Rhesus Monkey IFN-Alpha...
    Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
    5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
    MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
    Biology Products: